This Competitive Landscape Brief is a sample deliverable prepared by Avenbuan Bio Intelligence to illustrate the depth, sourcing rigour, and strategic framing we apply to client engagements. It is not investment advice and does not constitute medical advice.
All figures cited are from primary sources — SEC filings, FDA and EMA decisions, NICE technology appraisals, peer-reviewed journals (NEJM, The Lancet), IDA Ireland inward-investment announcements, and company investor disclosures. The source index in Appendix A allows independent verification of every quantitative claim.
All clinical, regulatory, and commercial data are current as of 18 May 2026 unless otherwise indicated. Subsequent events may materially affect the conclusions presented here. Client-commissioned versions of this brief are updated on a rolling basis aligned with quarterly disclosures and the principal clinical-conference calendar.
The GLP-1 receptor agonist market is the defining commercial story of pharma in the 2020s. Combined revenue from Novo Nordisk’s semaglutide franchise (Ozempic, Wegovy, Rybelsus) reached DKK 178.5 billion (~$25.8 billion) in FY2024.1 Eli Lilly’s tirzepatide franchise (Mounjaro, Zepbound) helped lift Lilly’s total revenue to ~$45.0 billion in the same period — a 32% year-on-year increase.2
A duopoly is forming, but it is not stable. SURMOUNT-5 — the first head-to-head trial — showed tirzepatide produced superior mean weight loss versus semaglutide (−20.2% vs −13.7% at 72 weeks).3 JPMorgan models the global incretin market at $200 billion by 2030,4 with daily oral pills, monthly injectables, and triple agonists each capable of redrawing the share map.
Three decisions cannot wait. First, the franchise economics of any cardiometabolic asset must be re-tested against a 25-million-patient US incretin population by 2030, not the 10 million on therapy in 2025. Second, oral and monthly administration is now table stakes — pipeline assets without a credible oral or extended-interval strategy face structural disadvantage. Third, the cash-pay channel and Medicare GLP-1 Bridge demonstration (effective 1 July 2026) materially change the access calculus for everything that follows.
The remainder of this brief sets out the evidence. Section 1 sizes the market. Section 2 profiles the duopoly. Section 3 ranks the eight pipeline challengers by probability-adjusted threat. Sections 4–6 cover clinical, regulatory, and manufacturing terrain. Section 7 distils five strategic imperatives. Section 8 sets out our 2030 base, bull, and bear cases.
GLP-1 receptor agonists have moved in less than a decade from a third-line Type 2 diabetes option to one of the largest drug categories in pharmaceutical history.
The transformation has been driven by three forces: clinical efficacy at thresholds previously associated with bariatric surgery; the demonstration of cardiovascular and metabolic benefits beyond weight; and a willingness among US payers, employers, and self-pay consumers to absorb list prices above $1,000 per month.
In FY2024 the two leading franchises generated combined revenue of approximately $26 billion from Ozempic and Wegovy alone,10 alongside the meaningful contribution of Lilly’s tirzepatide franchise to its $45 billion total. By Q3 2025, Lilly’s tirzepatide products were reporting quarterly worldwide revenue of $6.52 billion (Mounjaro) and $3.57 billion (Zepbound US) — annualised run-rates of $26 billion and $14 billion respectively.11
Forecasts diverge by a factor of more than two, reflecting genuine uncertainty about three drivers: government reimbursement, oral-formulation conversion rates, and persistence beyond year two of therapy.
| Forecaster | 2030/2035 forecast | Notes |
|---|---|---|
| JPMorgan Global Research | $200B (2030) | Global incretin market; 25M Americans on therapy by 20304 |
| Goldman Sachs Research | $95B (2030) | Anti-obesity only; US peak revised down to $70B; orals ~25% share12 |
| Morgan Stanley | $190B (2035) | T2D + obesity combined; +$40B upward revision13 |
| BMO Capital Markets | ~$150B (early 2030s) | Obesity only14 |
| EvaluatePharma | >$100B (2030) | Ozempic + Mounjaro + Wegovy + Zepbound + CagriSema15 |
| IQVIA | ~$130B (2034) | Global anti-obesity medications; 13–15% CAGR16 |
The United States remains the demand engine, contributing the majority of branded-GLP-1 revenue across both franchises. Europe is volume-constrained by reimbursement and HTA process rather than by underlying prevalence: NHS England moved to phased rollout of tirzepatide in March 2025 following NICE TA1026;18 HSE Ireland was not yet reimbursing Wegovy as of October 2025, with the Health Minister signalling an end-2025 target.19
Strategic plans built against a 2023-vintage TAM are now materially under-scoped. Any cardiometabolic strategy assessed today against pre-Wegovy market sizing will under-invest in three of the four hinge variables above. We recommend re-running base/bull/bear scenarios at the franchise level whenever a payer event, oral pivotal, or HTA decision moves the underlying assumption set.
Two companies — neither headquartered in the United States — account for the overwhelming majority of GLP-1 receptor-agonist revenue worldwide. Their competitive trajectories diverge in three respects: portfolio breadth, manufacturing strategy, and willingness to use direct-to-patient cash channels.
Novo Nordisk’s response to Lilly’s clinical lead has been to broaden formulations (oral plus injectable), broaden labels (CV, MASH), and broaden geographies (Catalent and Athlone). The bet is that a globally diversified semaglutide franchise — supplemented by CagriSema and the next-generation amycretin — can hold share against tirzepatide’s efficacy advantage.
Lilly is using its clinical lead to set a faster cadence than Novo can match: oral, monthly, and triple-agonist programmes are progressing in parallel, supported by what is effectively the largest cardiometabolic manufacturing build-out in industry history.
| Dimension | Novo Nordisk | Eli Lilly |
|---|---|---|
| Lead molecule | Semaglutide (GLP-1) | Tirzepatide (GIP/GLP-1) |
| Lead obesity brand | Wegovy (injectable + oral 25 mg) | Zepbound (injectable + LillyDirect vials) |
| FY2024 lead-franchise sales | ~$25.8B Ozempic+Wegovy+Rybelsus | Mounjaro + Zepbound, major share of $45B |
| Major label expansions 2024–26 | CV (Mar 2024); MASH (Apr 2025); Oral (Dec 2025) | OSA (Dec 2024); pipeline reads in HFpEF, addiction |
| Pipeline lead asset(s) | CagriSema (NDA Dec 2025); Amycretin | Retatrutide (P3); Orforglipron (P3 P1 readouts 2025) |
| Manufacturing strategy | Catalent fill-finish; Athlone tabletting €432m | Lebanon IN $9B; Feb 2025 $27B package; Kinsale/Limerick |
| Direct-to-patient channel | NovoCare Wegovy $349/month (post Nov 2025 framework) | LillyDirect Zepbound $299 starter, $399–$449 other doses |
In a fully reimbursed market with no manufacturing constraint, tirzepatide would be the default first-line choice for obesity management. The fact that semaglutide retains comparable share globally is therefore evidence of the persistent role of supply, brand, and physician familiarity — all factors that diminish over time.
Eight late-stage challengers warrant active monitoring. Two come from inside the duopoly. The remaining six are external. We score each on six attributes — efficacy, route, expected approval window, manufacturing scalability, label-expansion potential, and current development risk — and rank by probability-adjusted commercial threat.
| Asset (sponsor) | Differentiation | Threat | Watch item |
|---|---|---|---|
| Retatrutide (Lilly) | Highest efficacy in class; triple GIP/GLP-1/glucagon | High | Tolerability profile at top doses |
| Orforglipron (Lilly) | Oral non-peptide; scalable manufacturing | High | Real-world persistence vs injectables |
| MariTide (Amgen) | Monthly subcutaneous dosing | High | Phase 3 efficacy vs Phase 2 readouts |
| CagriSema (Novo) | GLP-1 + amylin combination; NDA filed Dec 2025 | Medium-High | Missed internal 25% weight-loss target |
| CT-388 (Roche) | Strong Phase 1b SC GLP-1/GIP | Medium | Phase 3 launch timing |
| AZD5004 / Elecoglipron (AstraZeneca) | Oral, well-resourced sponsor | Medium | ADA 2026 weight-loss data drop |
| VK2735 (Viking) | Independent dual-agonist option | Medium | Manufacturing scale-up |
| Survodutide (Boehringer/Zealand) | Strong dual MASH + obesity profile | Medium | MASH Phase 3 readouts |
| GSBR-1290 (Structure) | Oral small-molecule | Medium | Phase 2b ACCESS readout |
| Pemvidutide (Altimmune) | Best-in-class MASH profile | Niche (MASH) | Obesity P3 financing |
| Amycretin (Novo) | Unimolecular GLP-1 + amylin; SC and oral | High | Phase 3 design and timeline |
| Danuglipron (Pfizer) | — | Discontinued | Pfizer redirected to GIPR antagonist |
Triple agonist (GIP/GLP-1/glucagon). TRIUMPH-4 Phase 3: −28.7% mean weight loss at 12 mg over 68 weeks in obesity with knee osteoarthritis, with WOMAC pain reductions of up to 4.5 points. ~5,800 patients enrolled across the TRIUMPH programme; seven additional Phase 3 readouts expected through 2026. Likely FDA submission: late 2026 or 2027.27
Oral non-peptide GLP-1. ATTAIN-1 (n=3,127): 36.0% of patients at 36 mg achieved ≥15% body-weight loss at 72 weeks versus 5.9% on placebo. ATTAIN-2 (obesity + T2D): mean 10.5% / 22.9 lb weight loss at top dose; A1C reduction of 1.8%. Global regulatory submissions for obesity initiated in 2025; published in NEJM.28
Co-formulation of cagrilintide (amylin analogue) and semaglutide. REDEFINE 1 (n=3,417, 68 wk): −22.7% mean weight loss vs −16.1% semaglutide alone vs −11.8% cagrilintide alone vs placebo. The result fell short of Novo’s internal 25% target;36 nevertheless the NDA was filed with FDA in December 2025.37
Unimolecular GLP-1 + amylin. Subcutaneous Phase 1b/2a delivered up to −22% body weight at 36 weeks (Lancet, January 2025).38 Oral Phase 1 produced −13% body weight at 12 weeks. Phase 3 in T2D begins in 2026.
Peptide-antibody conjugate, monthly subcutaneous dosing. Phase 2 produced up to −20% mean weight loss in obesity without T2D and up to −17% in obesity with T2D (ADA 85th Scientific Sessions, June 2025).39 The Phase 3 MARITIME programme — plus dedicated Phase 3 OSA, ASCVD, and HFpEF studies — are recruiting. Monthly administration is the differentiator.
Roche acquired Carmot Therapeutics for $2.7 billion upfront in late 2023.40 CT-388 (SC GLP-1/GIP) produced −18.8% placebo-adjusted body-weight reduction at 24 weeks in Phase 1b; CT-996 (oral small-molecule GLP-1) showed −7.3% body-weight reduction at 4 weeks in Phase 1.41
In-licensed from Eccogene November 2023 ($185 million upfront, up to $1.8 billion milestones). Phase 2b VISTA (NCT06579092) and SOLSTICE (NCT06579105) both met primary endpoints; weight-loss data held until ADA June 2026. Progressing to Phase 3.42
Dual GLP-1/GIP. Phase 3 VANQUISH-1 (subcutaneous, ~4,650 obesity patients, 78 weeks) and VANQUISH-2 (~1,000 T2D + obesity patients) initiated Q2 2025. Oral VK2735 is in Phase 2.43
Oral small-molecule GLP-1. Phase 2a (n=64, 12 wk): −6.2% placebo-adjusted weight reduction in capsule formulation; −6.9% with tablet. Phase 2b ACCESS and ACCESS II read out Q4 2025.44
GLP-1/glucagon dual. IMPACT Phase 2b in MASH: up to 59.1% MASH resolution without worsening fibrosis; up to 34.5% fibrosis improvement at 24 weeks; weight loss up to −6.2%.45
GLP-1/glucagon dual. SYNCHRONIZE-1 Phase 3 in obesity: −16.6% mean weight loss. Up to 83% of MASH Phase 2 patients achieved liver-disease improvement without worsening fibrosis. FDA Breakthrough Therapy designation in MASH (September 2024).46
Pfizer discontinued danuglipron on 14 April 2025 following a single case of potentially drug-induced asymptomatic liver injury. Pfizer continues an oral GIPR antagonist programme but is no longer a near-term competitive threat.6
The single highest-probability disruption to the duopoly is a credible monthly subcutaneous agent (MariTide) or best-in-class triple agonist (retatrutide). The single highest-impact disruption is an oral programme with injectable-grade efficacy — either Lilly’s orforglipron or AstraZeneca’s elecoglipron. Whichever route wins, manufacturing scalability becomes the constraint.
The clinical-trial database below records every late-stage GLP-1 readout that has shaped competitive positioning since 2021. Each row is sourced to the publishing journal or sponsor announcement.
| Trial | Asset | Duration | Mean weight loss | Reference |
|---|---|---|---|---|
| STEP-1 | Semaglutide 2.4 mg | 68 wk | −14.9% (placebo −2.4%) | NEJM 202147 |
| SURMOUNT-1 | Tirzepatide 15 mg | 72 wk | −22.5% (placebo −2.4%) | NEJM 202248 |
| SELECT (CV outcomes) | Semaglutide 2.4 mg | median 39.8 mo | HR 0.80 MACE composite | NEJM 202349 |
| SURMOUNT-OSA | Tirzepatide 15 mg | 52 wk | −20% body weight; AHI −27.4 events/h | Lilly 202450 |
| SURMOUNT-5 (head-to-head) | Tirzepatide vs Sema | 72 wk | −20.2% vs −13.7% (p<0.001) | NEJM 20253 |
| ESSENCE (MASH) | Semaglutide 2.4 mg | 72 wk | 63% MASH resolution vs 34% pbo | NEJM Apr 202551 |
| REDEFINE 1 | CagriSema | 68 wk | −22.7% vs −16.1% sema vs −2.3% pbo | NEJM 202536 |
| ATTAIN-1 (oral) | Orforglipron 36 mg | 72 wk | 36% achieved ≥15% loss vs 5.9% pbo | NEJM 202528 |
| TRIUMPH-4 | Retatrutide 12 mg | 68 wk | −28.7% weight; WOMAC pain −4.5 | Lilly Dec 202527 |
SURMOUNT-5 is the most consequential trial of the post-launch era. By directly comparing tirzepatide to semaglutide at maximum tolerated doses in 751 patients over 72 weeks, the study removed comparator ambiguity from physician decision-making. Tirzepatide produced 47% more relative weight loss than semaglutide (−20.2% versus −13.7%) and had a more favourable gastrointestinal adverse-event discontinuation rate (2.7% vs 5.6%).
The commercial trajectory of a GLP-1 asset is now decided by reimbursement architecture as much as by clinical efficacy. The 2024–26 period has produced four reimbursement events that materially alter franchise valuation.
On 1 July 2026 the Centers for Medicare & Medicaid Services begins a demonstration providing Part D coverage of Wegovy and Zepbound for chronic weight management, capped at a $50 patient copay. Eligibility requires BMI ≥35 alone, or BMI ≥27 with specified clinical criteria. The demonstration runs through 31 December 2027 and does not cover the Wegovy cardiovascular indication or the Zepbound OSA indication.17
The demonstration is not a permanent statutory change. Sponsors should model the addressable Medicare population on a probability-weighted basis between (a) permanent post-demonstration extension, (b) limited extension to specific clinical sub-groups, and (c) sunset on 1 January 2028.
NICE TA1026 (December 2024) recommends tirzepatide for obesity management in NHS England, with an estimated 3.4 million people meeting eligibility criteria. NHS England issued interim commissioning guidance in March 2025 setting a phased implementation: 90 days for existing specialist weight-management services, 180 days for high-priority populations, and up to three years for expanded population groups.18
As of October 2025, neither Wegovy nor Mounjaro was reimbursable under HSE schemes (Medical Card, Long-Term Illness, Drug Payment Scheme). Patients pay €120–€475 per month privately. Health Minister Carroll MacNeill indicated an end-2025 target for Wegovy reimbursement.19
The takeaway is binary: either reimbursement is secured by H2 2026 and brand-share dynamics align with UK/EU markets, or Ireland remains a cash-pay outlier — with corresponding implications for franchise valuation and sales-force investment.
There is no harmonised EU reimbursement decision for GLP-1 weight-management indications. Germany, France, and Spain operate through individual HTA bodies (G-BA, HAS, AEMPS); reimbursement status varies markedly. Eastern European markets are predominantly cash-pay. The EMA centralised approval grants market authorisation but not reimbursement, which means franchise commercial leads must navigate ~27 HTA conversations rather than one.
FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage resolved on 21 February 2025. Enforcement discretion for 503A pharmacies ended in February and April 2025 respectively; 503B outsourcing facilities had until 19 March and 22 May 2025. The Outsourcing Facilities Association lawsuit challenging the semaglutide delisting did not produce preliminary injunctive relief.32
A White House framework in November 2025 produced concurrent price reductions in the direct-to-patient channel. NovoCare Pharmacy reduced Wegovy from $499 to $349 per month; LillyDirect introduced Zepbound vials at $299 (starter), $399 (5 mg), and $449 (other doses) from 1 December 2025.5,29 The channel is now a primary access route alongside payer-mediated distribution.
The GLP-1 manufacturing arms race is the single largest capacity expansion in pharmaceutical history. Sterile fill-finish and peptide / small-molecule API capacity have both been the binding constraint, and remain so for the next-generation oral and monthly programmes.
| Sponsor / site | Commitment | Purpose |
|---|---|---|
| Eli Lilly — Lebanon, IN | $9B (from $3.7B) | Tirzepatide API; ~900 FTEs33 |
| Eli Lilly — US package (Feb 2025) | $27B (4 new plants) | 3 API + 1 injectables; 3,000 FTEs + 10,000 construction jobs34 |
| Eli Lilly — Kinsale, Ireland | $800M completed | Tirzepatide production35 |
| Eli Lilly — Limerick, Ireland | $1.0B (Sept 2024) | Limerick expansion — total site investment now ~$2.0B |
| Eli Lilly — Concord, NC | $1B | New injectable plant |
| Novo Holdings — Catalent | $16.5B (closed Dec 2024) | 3 fill-finish sites to Novo Nordisk for $11B30 |
| Novo Nordisk — Athlone, Ireland | €432M (announced Mar 2026) | Oral Wegovy tabletting; ~600 construction jobs9 |
Ireland now hosts active GLP-1 manufacturing for both leading franchises and is the single most strategically central European location for the category. For clients evaluating European manufacturing footprint, Ireland offers (a) regulatory familiarity with both FDA and EMA inspections, (b) a deep contract-manufacturing ecosystem (with the residual Catalent sites now Novo Nordisk-owned), and (c) corporate-tax certainty under the OECD 15% floor.
API capacity for semaglutide and tirzepatide has materially expanded. The constraint now sits in sterile fill-finish — auto-injector assembly, vial fill, cartridge manufacture — and in the secondary packaging supply chain (needles, prefilled-pen assemblies, glass containers). The Catalent acquisition and the Lebanon expansion explicitly addressed this constraint; competitors without a captive fill-finish footprint will pay rising prices for contract capacity through 2027.
A Phase 3 asset entering the regulatory submission window in 2027 without secured fill-finish capacity will face a 12–18 month commercial launch delay regardless of approval. We recommend that emerging-biotech clients negotiate fill-finish capacity at Phase 2b — including the right of first refusal on second-source qualifications — rather than after pivotal-trial readout.
The findings of Sections 1 through 6 converge on five strategic imperatives for pharma and biotech leadership teams. Each is action-oriented; the time-horizon is the next 12 to 24 months.
JPMorgan now models 25 million Americans on GLP-1 therapy by 2030, against approximately 10 million in 2025. Any business case authored before mid-2024 likely under-states the addressable population by 2–3x. Re-run base, bull, and bear cases at the franchise level, incorporating (a) the Medicare GLP-1 Bridge demonstration window, (b) oral conversion sensitivities at 15%, 25%, and 40% of total volume, and (c) Year-2 persistence at 35%, 50%, and 65%.
The single most underrated constraint on the next-generation pipeline is sterile fill-finish. Innovator companies launching after 2027 without captive capacity, a long-term contract, or second-source qualifications will experience launch delays measured in quarters, not months. Treat fill-finish negotiation as a Phase 2b deliverable rather than a launch-readiness item.
Oral semaglutide is now approved for weight management; orforglipron submissions are in regulatory review; AZD5004 and GSBR-1290 will read out in 2025–2026. Within five years, the injectable-only asset will have lost optionality in two of the four largest payer markets. If your portfolio does not contain a credible oral or monthly programme, partner for one — and price the optionality value of doing so against the discounted franchise revenue of remaining injectable-only.
Beyond weight, the indications that meaningfully expand the payer rationale are cardiovascular event reduction (SELECT), obstructive sleep apnoea (SURMOUNT-OSA), MASH (ESSENCE), and — pending data — HFpEF, Alzheimer’s, kidney disease, and substance-use disorders. Each indication that survives a Phase 3 readout adds a defensible reimbursement conversation with payers. Price labels-in-development as commercial assets, not exploratory science.
Both leading sponsors have made a structural commitment to the cash-pay channel — Wegovy at $349/month, Zepbound at $299 starter through LillyDirect. The optionality argument for direct-to-patient is no longer theoretical. Clients with cardiometabolic franchises should decide explicitly (a) whether to operate a captive direct-to-patient channel, (b) which patient cohorts are best served by cash-pay versus payer-mediated access, and (c) the tier-discount logic against PBM rebates.
Avenbuan Bio Intelligence models three scenarios for the GLP-1 receptor-agonist market by 2030. Each scenario varies the four hinge variables identified in Section 1: reimbursement breadth, oral conversion, Year-2 persistence, and indication expansion.
| Variable | Bear case | Base case | Bull case |
|---|---|---|---|
| Total 2030 revenue | $95B | $130B | $200B |
| US Medicare GLP-1 Bridge | Sunset Dec 2027; no extension | Limited extension to BMI ≥35 + CV | Permanent statutory inclusion |
| Oral share of obesity | 15% | 25% | 40% |
| Year-2 persistence (US) | 35% | 50% | 65% |
| New approved indications | No further beyond MASH/OSA | Add HFpEF or kidney | Add HFpEF + AD + addiction |
| Duopoly share of market | 55% | 65% | 70% (network effects) |
The bear case is anchored to Goldman Sachs’ most recent revision of the anti-obesity-only market; the base case interpolates Morgan Stanley, EvaluatePharma, and IQVIA forecasts; the bull case follows JPMorgan’s $200 billion 2030 incretin figure. In all three scenarios, the duopoly accounts for the majority of total revenue, but the bear-case scenario sees aggressive share erosion from MariTide, retatrutide, and oral programmes outside the originator portfolios.
All quantitative claims in this brief are sourced to primary documents. Forecasts cited are presented as the work of the named institution at the date of publication. Avenbuan Bio Intelligence triangulates across at least three sources before placing a figure in our base case.
Avenbuan Bio Intelligence uses AI-assisted synthesis and source-extraction tools to accelerate analyst workflow. Every quantitative claim, however, passes through a four-stage human verification gate: (1) source traced to primary document; (2) figure verified against original; (3) date and context confirmed; (4) inclusion criteria for the specific claim. Claims that cannot pass all four gates are omitted.
Client-commissioned versions of this brief are updated on a rolling basis aligned with company quarterly disclosures, major regulatory decisions, and the principal clinical-conference calendar (JPM Healthcare Conference, ADA Scientific Sessions, EASD, ESMO).
Each entry below is a primary or near-primary source cited in this brief. Footnote numbers reference the citations in the body of the report.
Avenbuan Bio Intelligence is a Dublin-headquartered, AI-augmented competitive-intelligence firm serving pharma and biotech leaders across Ireland, the European Union, the United Kingdom, and the United States.
We combine doctorate-level scientific literacy, financial analyst rigour, and proprietary AI workflows to deliver McKinsey-grade strategic insight at the velocity that modern decision cycles demand.
Founded by Endrice Avenbuan. Bachelor’s (Moderatorship) in Medicinal Chemistry, Trinity College Dublin (Expected First Class Honours, 2026). Junior Analyst, Trinity Student Managed Fund — Healthcare & Pharmaceuticals sector (€500,000 AUM). Black Heritage Insight intern, BlackRock (London). Summer Talent Academy intern, Fidelity International (London). Wellcome Trust Biomedical Vacation Research Scholar, University of Manchester. Spring Intern, Citigroup (Dublin).
linkedin.com/in/endrice-avenbuan
Avenbuan Bio Intelligence operates a hybrid retainer/project model. Sample-grade deliverables — like the brief in your hands — illustrate the standard we apply to every client engagement.
Dublin · Ireland | hello@avenbuanbio.com | avenbuanbio.com
© 2026 Avenbuan Bio Intelligence. All rights reserved. This brief may be shared with prospective clients under the terms of fair use; redistribution for commercial purposes requires written permission. This report is for informational purposes only and does not constitute investment, medical, legal, or tax advice.